Katholieke Universiteit Leuven, Ku Leuven R&d

Lysando Ag

Universiteit Gent

Katholieke Universiteit Leuven

Consejo Superior De Investigaciones Cientificas

University of Minho

Rob Lavigne

Yves Briers

Stefan Miller

Maarten Walmagh

Guido Volckaert

Martin Griessl

Hans Gerstmans

Dennis Grimon

Leonardus Dorothea Kluskens

Silvio Roberto Branco Dos Santos

Beatriz MARTÍNEZ FERNÁNDEZ

Joana Cecilia Valente Rodrigues Azeredo

Lorena RODRÍGUEZ-Rubio

Diana GUTIÉRREZ FERNÁNDEZ

Ana RODRÍGUEZ GONZÁLEZ

Pilar GARCÍA SUÁREZ

It is a first object of the present invention to provide a method for preparing a Tile vector, being a vector, which comprises a selectable marker and a coding polynucleotide, wherein said coding polynucleotide is immediately preceded and followed by a type IIs recognition sequence, wherein said preceding and following recognition sequences are recognized by a same type IIs restriction enzyme, but have an opposite orientation. More particularly, the position and orientation of said preceding and following type IIs recognition sequences provides for the cleavage of said Tile vector by a corresponding type IIs restriction enzyme resulting in the release of said coding polynucleotide sequence having at its respective ends overhang sequences with a known orientation and length, while lacking said preceding and following type IIs recognition sequences. In a second object the present invention provides a method for using such Tile vectors obtained as previously described for joining two or more coding polynucleotides to form a product polynucleotide. Typically, said product polynucleotide is integrated in a vector.

Polynucleotide shuffling method

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

Antimicrobial agents

The present invention relates to polypeptides comprising an amino sequence selected from the group consisting of: SEQ ID NO: 1, and fragments and derivatives of these. The invention also relates to the corresponding nucleic acids vectors, host cells and compositions. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, host cells and compositions in a method for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body, in particular for the treatment or prevention of Gram-negative bacterial infections. The polypeptides, nucleic acids, vectors, host cells and compositions according to the invention may also be used as an antimicrobial in food or feed, or in cosmetics, as disinfecting agent or in the environmental field.

The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said endolysin variant as a diagnostic means in medicinal, food or feed or environmental diagnostic. Finally, the present invention relates to a pharmaceutical composition comprising said modified endolysin variant.

The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein.

Endolysin OBPgpLYS

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

Growing community of inventors

Merksem, Belgium

Rob Lavigne